Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Millendo Therapeutics to Present at J.P. Morgan Healthcare Conference

Wednesday, January 4, 2017   (0 Comments)
Posted by: Kate Oesterle
Share |

ANN ARBOR, Mich., January 3, 2017 – Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 3:00 p.m. PST in San Francisco, CA.

 

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are advancing two product candidates in five indications: MLE4901, designed to address Polycystic Ovary Syndrome (PCOS) and Vasomotor Symptoms (VMS), and ATR-101 for the treatment of Classic Congenital Adrenal Hyperplasia (CAH), Endogenous Cushing’s Syndrome (CS), and Adrenocortical Carcinoma (ACC). www.millendo.com

 

 

###

 

Media Contact:

Casey R. Doucette, Ph.D.

MacDougall Biomedical Communications

+1 781 235 3060

cdoucette@macbiocom.com

 

Investor Contact:

Christina Tartaglia

Stern Investor Relations

+1 212 362 1200

christina@sternir.com


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal